VBI Vaccines, Inc. (VBIV)
| Market Cap | 688.35M |
| Revenue (ttm) | 1.06M |
| Net Income (ttm) | -46.23M |
| Shares Out | 254.00M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $2.63 |
| Previous Close | $2.71 |
| Change ($) | -0.09 |
| Change (%) | -3.14% |
| Day's Open | 2.71 |
| Day's Range | 2.62 - 2.81 |
| Day's Volume | 1,853,291 |
| 52-Week Range | 1.02 - 6.93 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...
The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIV) entered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candid...
VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.
OSLO, Norway & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. (Nasdaq: VBIV), today announced a partnership to develop VBI'...
VBI Vaccines Inc (NASDAQ: VBIV) initiates enrollment in Phase 1/2 study of VBI-2902, its monovalent enveloped virus-like particle (eVLP), COVID-19 vaccine candidate. The adaptive 60-subject study will e...
OTTAWA, Ontario--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today...
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -62.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's k...
VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings is ...
The company reported good news from a study of its hepatitis B vaccine.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GNUS) Hertz ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.
CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vac...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacci...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
Here's why investors should stay away from some of the riskiest coronavirus stocks on the market.
Neither biotech is in the front of the pack in developing a COVID-19 vaccine.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.95, marking a +0.68% move from the previous day.
In the race for a vaccine, a pause in progress sets you back.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.98, marking a +0.68% move from the previous day.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...
VBI Vaccines, Inc. (VBIV) closed the most recent trading day at $3.76, making no change from the previous trading session.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
The biotech will present additional data for one of its pipeline candidates later this week.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
VBI Vaccines, Inc. (VBIV) closed at $3.12 in the latest trading session, marking a +0.65% move from the prior day.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.
Investors who are looking for promising coronavirus vaccine stocks should keep an eye out for this emerging biotech.
About VBIV
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP progr... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol VBIV |
Financial Performance
In 2020, VBI Vaccines's revenue was $1.06 million, a decrease of -52.23% compared to the previous year's $2.22 million. Losses were -$46.23 million, -15.66% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for VBI Vaccines stock is "Strong Buy." The 12-month stock price forecast is 7.50, which is an increase of 185.71% from the latest price.